Evolus, Inc. (EOLS)
EOLS moved a median of +0.08% 30 minutes after news, and 0.00% by the close. How EOLS actually reacts to news — the realized, point-in-time move the market made, measured across 275 labeled events over the last three years with zero look-ahead.
EOLS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 274 |
| 30-min | +0.08% | 51% | 275 |
| 60-min | -0.22% | 44% | 275 |
| to close | 0.00% | 46% | 274 |
| Middle 50% of EOLS reactions | -0.92% to +0.81% |
|---|---|
| Median reaction (30-min) | +0.08% |
| Measured reactions | 275 |
Half of all Evolus, Inc. news events land between -0.92% and +0.81% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when EOLS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to EOLS's baseline. Nothing else.
Recent EOLS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Encourages Evolus, Inc. (EOLS) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.07% | -1.37% | |
| Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program | Press release | Business Wire | +0.54% | -2.69% | |
| EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law | Press release | Business Wire | -0.52% | -0.13% | |
| Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes | Press release | Business Wire | +0.76% | -2.54% | |
| Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook | Press release | Business Wire | -2.86% | +6.01% | |
| Form 10-Q Evolus, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.86% | +6.01% | |
| Form 8-K Evolus, Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -2.86% | +6.01% | |
| Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand | Press release | Business Wire | +0.98% | +0.33% | |
| Form 8-K Evolus, Inc. For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +0.98% | +0.33% | |
| Evolus to Report Second Quarter Financial Results on August 5, 2026 | Press release | Business Wire | -0.17% | +1.38% | |
| Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.21% | -1.36% | |
| Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality | Press release | Business Wire | +0.14% | -2.02% | |
| Form 8-K Evolus, Inc. For: Jul 07 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | -2.02% | |
| Form EFFECT Evolus, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.92% | -0.15% | |
| Form 8-K Evolus, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -1.92% | -0.15% | |
| Form S-3 Evolus, Inc. | SEC filing · Form S-3 | SEC EDGAR | -0.38% | +0.60% | |
| Evolus to Participate in The Jefferies Global Healthcare Conference | Press release | Business Wire | -1.52% | -1.98% | |
| Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe | Press release | Business Wire | +1.10% | -0.63% | |
| Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook | Press release | Business Wire | +10.34% | +15.61% | |
| Form 10-Q Evolus, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +10.34% | +15.61% | |
| Form 8-K Evolus, Inc. For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +10.34% | +15.61% | |
| Form ARS Evolus, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.12% | -3.36% | |
| Form DEF 14A Evolus, Inc. For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | -0.75% | -3.36% | |
| Form DEFA14A Evolus, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.75% | -3.36% | |
| Evolus to Report First Quarter Financial Results on May 4, 2026 | Press release | Business Wire | +2.54% | +2.54% | |
| Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference | Press release | Business Wire | +0.63% | +2.75% | |
| Aviva Aesthetics Partners with Nationally Recognized Injector Jordan White and Urban Medical, Expanding into Arizona and Virginia | Press release | PR Web | +0.13% | +0.25% | |
| Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.65% | +0.65% | |
| Form 8-K Evolus, Inc. For: Mar 13 | SEC filing · Form 8-K | SEC EDGAR | -2.18% | -0.20% | |
| Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026 | Press release | Business Wire | +8.18% | +5.47% | |
| Form 10-K Evolus, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +8.18% | +5.47% | |
| Form 8-K Evolus, Inc. For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | +8.18% | +5.47% | |
| Form S-8 Evolus, Inc. | SEC filing · Form S-8 | SEC EDGAR | +8.18% | +5.47% | |
| Evolus to Participate in The Leerink Partners Global Healthcare Conference | Press release | Business Wire | +0.23% | +4.41% | |
| Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026 | Press release | Business Wire | -0.23% | +0.92% | |
| Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.23% | +0.92% | |
| Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue | Press release | Business Wire | -0.35% | +0.18% | |
| Form 8-K Evolus, Inc. For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | -0.35% | +0.18% | |
| Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.98% | -2.66% | |
| Moxie Announces Aesthetic Business Advisory Board and Scale Society Community to Shape the Next Era of Aesthetic Medicine | Press release | PR Web | -0.62% | +0.14% | |
| Evolus Reports Third Quarter 2025 Financial Results | Press release | Business Wire | -0.46% | -6.14% | |
| Form 10-Q Evolus, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.46% | -6.14% | |
| Form 8-K Evolus, Inc. For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | -0.46% | -6.14% | |
| Evolus to Participate in 2025 Stifel Healthcare Conference | Press release | Business Wire | -0.98% | -1.54% | |
| Evolus to Report Third Quarter Financial Results on November 5, 2025 | Press release | Business Wire | +2.09% | +1.94% | |
| Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.06% | -2.44% | |
| Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch | Press release | PR Newswire | -1.58% | +0.48% | |
| Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.90% | -7.92% | |
| Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer | Press release | Business Wire | -0.72% | +0.00% | |
| Form 8-K Evolus, Inc. For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | -0.72% | +0.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the EOLS section they belong to.
Where else EOLS is measured.
EOLS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Anika Therapeutics Inc. (ANIK) | 275 | +0.07% | 52% |
| Delcath Systems, Inc. (DCTH) | 275 | -0.27% | 42% |
| LivaNova PLC - Ordinary Shares (LIVN) | 275 | +0.04% | 51% |
| Puma Biotechnology Inc (PBYI) | 274 | +0.44% | 55% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Evolus, Inc.'s median reaction calculated?
Every labeled EOLS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 275 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of EOLS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does EOLS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.